Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Benign prostatic hyperplasia
Lower urinary tract symptoms of BPH
Silodosin
Tadalafil
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
31
07
2021
accepted:
01
06
2022
pubmed:
1
7
2022
medline:
16
7
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
Men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), will have deterioration in the quality of life. Likewise, BPH can be complicated by damage to bladder function, bladder stones formation, hematuria, and impaired kidney function. The goal of treatment is to avoid all those effects caused by BPH. To evaluate the efficacy of tadalafil alone, silodosin alone, and the combination of both in the treatment of LUTS associated with BPH. Patients in our department with BPH who had LUTS were assigned randomly to three groups: A (101 patients) received tadalafil, 5 mg; B (102 patients) received silodosin, 8 mg; and group C (105 patients) received the combination of tadalafil, 5 mg, and silodosin, 8 mg. For all participants, we asses changes in the maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF) score, Post-voiding urine (PVR) and all results were recorded and analyzed with the (SPSS) and Microsoft Excel 2010. Qmax, IPSS, PVR and IIEF score improved significantly more with the combination of tadalafil and silodosin than with either drug alone (p < 0.001). Three months after treatment, the mean Qmax values were 14.4 ml/sec in group A, 15.2 ml/sec in group B, and 15.8 ml/sec in group C; and the mean IPSSs were 17.6 in group A, 16.7 in group B, and 15.6 in group C (p < 0.001). Tadalafil and silodosin are effective treatment options in men with BPH who have LUTS, but the combination of both is more effective and feasible in treating LUTS of BPH.
Sections du résumé
BACKGROUND
BACKGROUND
Men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), will have deterioration in the quality of life. Likewise, BPH can be complicated by damage to bladder function, bladder stones formation, hematuria, and impaired kidney function. The goal of treatment is to avoid all those effects caused by BPH.
OBJECTIVE
OBJECTIVE
To evaluate the efficacy of tadalafil alone, silodosin alone, and the combination of both in the treatment of LUTS associated with BPH.
PATIENTS AND METHODS
METHODS
Patients in our department with BPH who had LUTS were assigned randomly to three groups: A (101 patients) received tadalafil, 5 mg; B (102 patients) received silodosin, 8 mg; and group C (105 patients) received the combination of tadalafil, 5 mg, and silodosin, 8 mg. For all participants, we asses changes in the maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF) score, Post-voiding urine (PVR) and all results were recorded and analyzed with the (SPSS) and Microsoft Excel 2010.
RESULTS
RESULTS
Qmax, IPSS, PVR and IIEF score improved significantly more with the combination of tadalafil and silodosin than with either drug alone (p < 0.001). Three months after treatment, the mean Qmax values were 14.4 ml/sec in group A, 15.2 ml/sec in group B, and 15.8 ml/sec in group C; and the mean IPSSs were 17.6 in group A, 16.7 in group B, and 15.6 in group C (p < 0.001).
CONCLUSION
CONCLUSIONS
Tadalafil and silodosin are effective treatment options in men with BPH who have LUTS, but the combination of both is more effective and feasible in treating LUTS of BPH.
Identifiants
pubmed: 35773357
doi: 10.1007/s00345-022-04071-7
pii: 10.1007/s00345-022-04071-7
pmc: PMC9279271
doi:
Substances chimiques
Indoles
0
Phosphodiesterase 5 Inhibitors
0
Tadalafil
742SXX0ICT
silodosin
CUZ39LUY82
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2063-2070Informations de copyright
© 2022. The Author(s).
Références
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N J Med 349(25):2387–2398
doi: 10.1056/NEJMoa030656
Gravas S (Chair), Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, Rieken M, Speakman MJ, Tikkinen KAO et al (2022) EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5.
Matsukawa Y, Hattori R, Sassa N, Yamamoto T, Gotoh M (2013) What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? Investigation using a pressure-flow study. Neurourol Urodyn 32(3):266–270
doi: 10.1002/nau.22286
Yokoyama O, Yoshida M, Kim SC, Wang CJ, Imaoka T, Morisaki Y, Viktrup L (2013) Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo and tamsulosin controlled 12-week study in Asian men. Int J Urol 20:193
doi: 10.1111/j.1442-2042.2012.03130.x
MacDonald R, Brasure M, Dahm P, Olson CM, Nelson VA, Fink HA et al (2019) Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review. Aging Male 22(1):1–11
doi: 10.1080/13685538.2018.1434503
Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M et al (2016) latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 70(1):124–133
doi: 10.1016/j.eururo.2015.12.048
Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB et al (2013) Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate 73:428–441
doi: 10.1002/pros.22584
Laydner HK, Oliveira P, Oliveira CR, Makarawo TP, Andrade WS, Tannus M, Araújo JL (2011) Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU Int 107:1104–1109
doi: 10.1111/j.1464-410X.2010.09698.x
Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ et al (2014) Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int 113(4):623–635
doi: 10.1111/bju.12500
Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E (2009) Efficacy, and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the preliminary report. J Sex Med 6:544–552
doi: 10.1111/j.1743-6109.2008.01109.x
Capogrosso P, Serino A, Ventimiglia E et al (2015) Effects of silodosin on sexual function - realistic picture from the everyday clinical practice. Andrology 3:1076–1081
doi: 10.1111/andr.12095
Sokhal AK, Sankhwar S, Goel A, Singh K, Kumar M, Purkait B, Saini DK (2018) A prospective study to evaluate sexual dysfunction and enlargement of seminal vesicles in sexually active men treated for benign prostatic hyperplasia by alpha-blockers. Urology 1(118):92–97
doi: 10.1016/j.urology.2017.08.025
Cihan A, Kazaz İO, Yıldırım Ö, Deliktaş H, Ongün Ş, Gül Ü, Şahin B, Üre İ, Özkara H (2020) Changing aspects of male sexual functions accompanying treatment of benign prostatic hyperplasia with silodosin 8 mg per day. J Sex Med 17(6):1094–1100
doi: 10.1016/j.jsxm.2020.02.023
Bastaskın T, Kaya E, Ozakca I, Yilmaz D, Bayatlı N, Akdemir AO, Gur S (2017) Effects of silodosin, a selective alpha-1A adrenoceptor antagonist, on erectile function in a rat model of partial bladder outlet obstruction. Neurourol Urodyn 36(3):597–603
doi: 10.1002/nau.23015
Sertkaya Z, Ozkaya F (2019) Silodosin has nocebo effect on sexual adverse effects: a randomized controlled trial. Eurasian J Med 51(3):277–279
doi: 10.5152/eurasianjmed.2019.19139
Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61(5):994–1003
doi: 10.1016/j.eururo.2012.02.033
Kaplan S, Gonzalez R, Te A (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723
doi: 10.1016/j.eururo.2007.01.033